Safety and efficacy of pediatric growth hormone therapy: Results from the full KIGS cohort
CONCLUSION: Data from KIGS, the largest and longest running international database of rhGH-treated children, show that rhGH is safe and increases short-term height gain and adult height across GHD and non-GHD conditions.PMID:36102184 | DOI:10.1210/clinem/dgac517 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 14, 2022 Category: Endocrinology Authors: Mohamad Maghnie Michael B Ranke Mitchell E Geffner Elpis Vlachopapadopoulou Lourdes Ib áñez Martin Carlsson Wayne Cutfield Raoul Rooman Roy Gomez Michael P Wajnrajch Agn ès Linglart Renata Stawerska Peter E Clayton Feyza Darendeliler Anita C S Hokken-K Source Type: research
Safety and efficacy of pediatric growth hormone therapy: Results from the full KIGS cohort
CONCLUSION: Data from KIGS, the largest and longest running international database of rhGH-treated children, show that rhGH is safe and increases short-term height gain and adult height across GHD and non-GHD conditions.PMID:36102184 | DOI:10.1210/clinem/dgac517 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 14, 2022 Category: Endocrinology Authors: Mohamad Maghnie Michael B Ranke Mitchell E Geffner Elpis Vlachopapadopoulou Lourdes Ib áñez Martin Carlsson Wayne Cutfield Raoul Rooman Roy Gomez Michael P Wajnrajch Agn ès Linglart Renata Stawerska Peter E Clayton Feyza Darendeliler Anita C S Hokken-K Source Type: research
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
ConclusionsChanges in pricing policy and the public reimbursement scheme related to the market entry of biosimilars were the main reasons for the decrease in the prices of reference products. Therefore, biosimilars did not generate genuine price competition between biological products. In many of the drug groups examined, the market shares of biosimilars have growth potential in the future. (Source: BioDrugs)
Source: BioDrugs - July 6, 2022 Category: Drugs & Pharmacology Source Type: research
Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency
CONCLUSIONS: This study extends knowledge of the somapacitan dose-IGF-I response and provides information on clinical dosing of once-weekly somapacitan in patients with AGHD.PMID:35521713 | DOI:10.1530/EJE-21-1167 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - May 6, 2022 Category: Endocrinology Authors: Rasmus Juul Kildemoes Christian Hollensen Beverly M K Biller Gudmundur Johannsson Yutaka Takahashi Michael H øjby Rasmussen Source Type: research
Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency
CONCLUSIONS: This study extends knowledge of the somapacitan dose-IGF-I response and provides information on clinical dosing of once-weekly somapacitan in patients with AGHD.PMID:35521713 | DOI:10.1530/EJE-21-1167 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - May 6, 2022 Category: Endocrinology Authors: Rasmus Juul Kildemoes Christian Hollensen Beverly M K Biller Gudmundur Johannsson Yutaka Takahashi Michael H øjby Rasmussen Source Type: research
Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency
CONCLUSIONS: This study extends knowledge of the somapacitan dose-IGF-I response and provides information on clinical dosing of once-weekly somapacitan in patients with AGHD.PMID:35521713 | DOI:10.1530/EJE-21-1167 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - May 6, 2022 Category: Endocrinology Authors: Rasmus Juul Kildemoes Christian Hollensen Beverly M K Biller Gudmundur Johannsson Yutaka Takahashi Michael H øjby Rasmussen Source Type: research
Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency
CONCLUSIONS: This study extends knowledge of the somapacitan dose-IGF-I response and provides information on clinical dosing of once-weekly somapacitan in patients with AGHD.PMID:35521713 | DOI:10.1530/EJE-21-1167 (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - May 6, 2022 Category: Endocrinology Authors: Rasmus Juul Kildemoes Christian Hollensen Beverly M K Biller Gudmundur Johannsson Yutaka Takahashi Michael H øjby Rasmussen Source Type: research
A Randomized Controlled Phase 3 Study on the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Idiopathic Short Stature
ConclusionsDaily subcutaneous administration of somatropin at 0.05 mg/kg/day for 52 weeks demonstrated improvement in growth outcomes and was well tolerated with a favorable safety profile.Trial RegistrationClinicalTrials.gov (identifier: NCT03635580). URL: https://clinicaltrials.gov/ct2/show/NCT03635580 (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - April 29, 2022 Category: Endocrinology Source Type: research
Suboptimal adherence to prescribed daily growth hormone regimen among Medicaid beneficiaries in the United States
CONCLUSIONS: Sociodemographic characteristics may be risk factors for suboptimal adherence and/or discontinuation of prescribed somatropin therapy. Improving GH regimen adherence among this at-risk population, and specifically among subgroups at highest risk, is warranted to improve clinical outcomes.PMID:35477409 | DOI:10.1080/03007995.2022.2070378 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 28, 2022 Category: Research Authors: Jane Loftus Yong Chen Anu Gupta Michael P Wajnrajch Jose Ma J Alvir Lawrence A Silverman Priti Jhingran Mahesh Kumar Sapna Prasad Source Type: research
SP8 Pharmacist-led centralised prescribing service for paediatric growth hormone in South Wales
Conclusion
Pharmacist-led prescribing of growth hormone can reduce the burden on consultants, specialist nurses, and GP’s, and standardise the supply and support that patients and their families receive when starting growth hormone. Ensuring patients receive treatment in a timely manner and receive appropriate monitoring regardless of where they live. Supplying growth hormone via homecare is more cost-effective than supplying via primary care. Utilising a pharmacist to oversee this service, identify and approach patients and their families to transition over to the new service can achieve significant cost savings to ...
Source: Archives of Disease in Childhood - April 20, 2022 Category: Pediatrics Authors: Burrows, R. Tags: Oral presentations Source Type: research
Safety and Efficacy of Lonapegsomatropin in Children with Growth Hormone Deficiency: enliGHten Trial 2-Year Results
CONCLUSIONS: Treatment with lonapegsomatropin continued to be safe and well-tolerated, with no new safety signals identified. Children treated with once-weekly lonapegsomatropin showed continued improvement of height SDS through the 2nd year of therapy without excess advancement of bone age.PMID:35428884 | DOI:10.1210/clinem/dgac217 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 16, 2022 Category: Endocrinology Authors: Aristides K Maniatis Samuel J Casella Ulhas M Nadgir Paul L Hofman Paul Saenger Elena D Chertock Elena M Aghajanova Maria Korpal-Szczyrska Elpis Vlachopapadopoulou Oleg Malievskiy Tetyana Chaychenko Marco Cappa Wenjie Song Meng Mao Per Holse Mygind Alden Source Type: research
Safety and Efficacy of Lonapegsomatropin in Children with Growth Hormone Deficiency: enliGHten Trial 2-Year Results
CONCLUSIONS: Treatment with lonapegsomatropin continued to be safe and well-tolerated, with no new safety signals identified. Children treated with once-weekly lonapegsomatropin showed continued improvement of height SDS through the 2nd year of therapy without excess advancement of bone age.PMID:35428884 | DOI:10.1210/clinem/dgac217 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 16, 2022 Category: Endocrinology Authors: Aristides K Maniatis Samuel J Casella Ulhas M Nadgir Paul L Hofman Paul Saenger Elena D Chertock Elena M Aghajanova Maria Korpal-Szczyrska Elpis Vlachopapadopoulou Oleg Malievskiy Tetyana Chaychenko Marco Cappa Wenjie Song Meng Mao Per Holse Mygind Alden Source Type: research
Safety and Efficacy of Lonapegsomatropin in Children with Growth Hormone Deficiency: enliGHten Trial 2-Year Results
CONCLUSIONS: Treatment with lonapegsomatropin continued to be safe and well-tolerated, with no new safety signals identified. Children treated with once-weekly lonapegsomatropin showed continued improvement of height SDS through the 2nd year of therapy without excess advancement of bone age.PMID:35428884 | DOI:10.1210/clinem/dgac217 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 16, 2022 Category: Endocrinology Authors: Aristides K Maniatis Samuel J Casella Ulhas M Nadgir Paul L Hofman Paul Saenger Elena D Chertock Elena M Aghajanova Maria Korpal-Szczyrska Elpis Vlachopapadopoulou Oleg Malievskiy Tetyana Chaychenko Marco Cappa Wenjie Song Meng Mao Per Holse Mygind Alden Source Type: research
